Cedric Lorenz Hugelshofer

Title: Cedric Lorenz Hugelshofer: Innovator in Pharmaceutical Science

Introduction

Cedric Lorenz Hugelshofer is a notable inventor based in Oakland, CA. He has made significant contributions to the field of pharmaceutical science, particularly in the development of compounds that target various metabolic diseases. With a total of two patents to his name, Hugelshofer's work is paving the way for new treatment options.

Latest Patents

Hugelshofer's latest patents focus on Diacylglyceride O-acyltransferase 2 (DGAT2) inhibitors. These inventions include compounds of formula I and their pharmaceutically acceptable salts, esters, and prodrugs. The patents also detail methods for synthesizing these compounds, as well as pharmaceutical compositions that incorporate them. The applications of these compounds are extensive, targeting conditions such as hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, and cardiorenal diseases like chronic kidney disease and heart failure.

Career Highlights

Hugelshofer is currently employed at Merck Sharp & Dohme Corporation, where he continues to innovate in the pharmaceutical sector. His work is characterized by a commitment to addressing complex health issues through scientific research and development.

Collaborations

Throughout his career, Hugelshofer has collaborated with esteemed colleagues, including Victor W. Mak and James Patrick Roane. These partnerships have contributed to the advancement of his research and the successful development of his patented compounds.

Conclusion

Cedric Lorenz Hugelshofer is a prominent figure in the field of pharmaceutical innovation, with a focus on developing treatments for serious health conditions. His contributions through patents and collaborations highlight his dedication to improving patient outcomes.